Immunological tolerance as an adjunct to allogeneic tissue grafting.
Since its clinical inception, our group has worked in clinical and experimental transplantation. The exciting early results of composite tissue allografts (CTA) attracted our attention during the 1980s, when some of the first experimental CTA literature appeared. The recent extraordinary results of clinical CTA grafts, primarily the Louisville and Lyon results, have been highlighted at this meeting. Interestingly, this success followed not long after the first International meeting in Louisville in 1997. This is clearly an exciting new application of transplant techniques to one of the newest and most unique types of transplants. Previous studies used immunosuppression for skin allografting. Early results seem quite exciting and we expect to see a rapid growth of interest and activity in this area. We believe that the entire field would benefit from the novel, highly effective and minimally toxic immune tolerance induction using CD3-immunotoxin (CD3-IT) and deoxyspergualin (DSG).
Thomas
F
F
Division of Transplant Immunology, Department of Surgery, University of Alabama, Birmingham, Alabama, USA.
Ray
P
P
Thomas
J M
JM
D000818:Animals; D017252:CD3 Complex / Q000276:immunology; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000922:Immunotoxins / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology; D008253:Macaca mulatta; D016378:Tissue Transplantation; D014184:Transplantation, Homologous
D017252:CD3 Complex; D006146:Guanidines; D007166:Immunosuppressive Agents; D000922:Immunotoxins; C037258:gusperimus